LiquidHALLMARK®: A Swift, Simple and Sensitive Liquid Biopsy Test for Personalized Cancer Care
LiquidHALLMARK® is Lucence’s flagship next-generation sequencing test for genomic profiling of solid tumors. Through a non-invasive blood draw, personalised patient results are delivered in 8 working days. LiquidHALLMARK provides important information for cancer care especially when tissue by invasive biopsy is insufficient or inaccessible.
LiquidHALLMARK profiles ctDNA mutations in 80 genes, including fusions in 10 genes, that are commonly associated with 15 major cancers including lung, breast, and colon.
LiquidHALLMARK® runs on its proprietary AmpliMARK™ technology. AmpliMARK is the foundational error-correction technology that uses unique molecular barcodes designed to improve the detection of multiple mutation types like single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), fusions and microsatellite instability (MSI).
AmpliMARK enables 0.1% mutation detection limit in plasma. At 0.1% limit of detection (LOD) for SNVs and indels, LiquidHALLMARK identifies more actionable mutations allowing physicians to make informed decisions to guide care across the whole patient journey.
Find out more: